The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.
Heterosexual transmission of human immunodeficiency virus remains the major route of transmission worldwide; thus, there is an urgent need for additional prevention strategies, particularly those that could be controlled by women. Using cellular and tissue explant models, we have evaluated the potential activity of thiocarboxanilide nonnucleoside analogue reverse transcriptase inhibitor UC-781 as a vaginal microbicide. We were able to demonstrate a potent dose-dependent effect against R5 and X4 infections of T cells. In human cervical explant cultures, UC-781 was not only able to inhibit direct infection of mucosal tissue but was able to prevent dissemination of virus by migratory cells. UC-781 formulated into a carbopol gel (0.1%) retained significant activity against both direct tissue infection and transinfection mediated by migratory cells. Furthermore, UC-781 demonstrated prolonged inhibitory effects able to prevent both localized and disseminated infections up to 6 days post compound treatment. Additional studies were carried out to determine the concentration of compound that might be required to block a primary infection within draining lymph nodes. While a greater dose of compound was required to inhibit both X4 and R5 infections of lymphoid versus cervical explants, this was equivalent to a 1:3,000 dilution of the 0.1% formulation. Furthermore, a 2-h exposure to the compound prevented infection of lymphoid tissue when challenged up to 2 days later. The prolonged protection observed following pretreatment of both genital and lymphoid tissues with UC-781 suggests that this class of inhibitors may have unique advantages over other classes of potential microbicide candidates.
Fletcher
Patricia
P
Division of Infectious Diseases, Cellular and Molecular Medicine, St George's, University of London, UK.
Kiselyeva
Yana
Y
Wallace
Greg
G
Romano
Joseph
J
Griffin
George
G
Margolis
Leonid
L
Shattock
Robin
R
D000180:Acrylic Resins; D000813:Anilides / Q000494:pharmacology*; D002478:Cells, Cultured; D002584:Cervix Uteri / Q000166:cytology / Q000276:immunology / Q000821:virology; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000494:pharmacology; D005260:Female; D005663:Furans / Q000494:pharmacology*; D005782:Gels / Q000494:pharmacology; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008221:Lymphoid Tissue / Q000821:virology; D011145:Polyvinyls / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D013854:Thioamides; D013997:Time Factors
D000180:Acrylic Resins; D000813:Anilides; D004337:Drug Carriers; D005663:Furans; D005782:Gels; D011145:Polyvinyls; D018894:Reverse Transcriptase Inhibitors; D013854:Thioamides; C006912:carboxypolymethylene; C100668:UC-781